MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Alvotech SA

Ouvert

SecteurSoins de santé

8.07 -1.71

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.06

Max

8.44

Chiffres clés

By Trading Economics

Revenu

-56M

-67M

Ventes

48M

151M

BPA

-0.24

Marge bénéficiaire

-44.289

Employés

1,012

EBITDA

-258M

-120M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+139.23% upside

Dividendes

By Dow Jones

Prochains Résultats

20 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-976M

2.5B

Ouverture précédente

9.78

Clôture précédente

8.07

Alvotech SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 avr. 2025, 14:54 UTC

Résultats

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

7 mai 2024, 20:30 UTC

Actualités

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Comparaison

Variation de prix

Alvotech SA prévision

Objectif de Prix

By TipRanks

139.23% hausse

Prévisions sur 12 Mois

Moyen 20 USD  139.23%

Haut 28 USD

Bas 14 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.